Login

I cannot remember my username

Our New Website Is Here!
As part of our merger with St. Paul Research, we’ve created a new website that will house all of our collective content under one roof, bringing you a higher level of research and service through our analysts’ combined insight, expertise, and perspective. Go to my.stpaulresearch.com to access our new site.

Ray Blanco’s FDA Profit Alert

Ray Blanco's FDA Profit Alert focuses on medical tech stocks with prices that move based on triggers generally unknown to the market.

It is designed to alert you to breakout moves could ultimately drive huge stock market gains...

Flash Sell! Book 44% Gains ASAP

Ray Blanco
By Ray BlancoPosted January 26, 2021

Our Flash Approval Indicator crunches millions of market data points, allowing us to peer into derivative trades made by people “in the know” ahead of FDA rulings. It registered a strong spike earlier this month, suggesting that insider money was pouring into the name. Today, we book that trade for a quick 50% winner!

You Must Be A Subscriber To View This Content.

If you are already a subscriber, click the login button below to get access. Not yet a subscriber? Checkout our publication below and get access today!

Ray Blanco’s FDA Profit Alert

The FDA Profit Alert focuses on medical tech stocks with prices that move based on triggers generally unknown to the market. It is designed to alert you to breakout moves in the medical markets that could ultimately drive huge stock market gains. It’s the single best way to connect the dots that link today’s dynamic, innovative medical market.

LoginGet Access

Ray Blanco

Ray Blanco

Ray Blanco is the editor of Technology Profits Confidential as well as Breakthrough Technology Alert, FDA Profit Alert, and Technology Profits Daily. Ray has been with Seven Figure Publishing since 2010. In 2019, his closed positions in Technology Profits Confidential outperformed the S&P500 by 50%.

View More By Ray Blanco

Related Posts

Flash Sell! Take Gains on This Pharma Play

Ray Blanco
By Ray BlancoPosted July 25, 2018

Clinical trials are generally set up with guidance and input from the FDA, in order to have something that the regulator finds acceptable as the basis for a drug approval. One biotech is deviating from that protocol, and is sending shares swooning…

TOPICS | , , ,

Important: Ebola Stock Trading Action Alert #2

Paul Mampilly
By Paul MampillyPosted October 3, 2014

Yesterday, I told you that I believe that ebola problem in the US is growing. This is different than what the government is telling you. But the facts continue to support my view. Last night, we got more bad news from the government. Now, the government is saying that as many as 100 people are being screened for ebola in Dallas. Now, we also know that emergency workers that came to treat the first patient, Thomas Eric Duncan, are exposed...

TOPICS | , , ,